			Home About us Contact

Acute Bronchitis (acute + bronchitis)

Distribution by Scientific Domains

Medical Sciences	100%

Selected Abstracts

Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, Issue 2 2007
B. Müller
Abstract Background, Vasopressin has haemodynamic as well as osmoregulatory effects, and reflects the individual stress response. Copeptin is cosynthesized with vasopressin, directly mirroring vasopressin levels, but is more stable in plasma and serum. Both levels are increased in patients with septic shock. Lower respiratory tract infections (LRTI) are a precursor of sepsis. Thus, we investigated circulating levels and the prognostic use of copeptin for the severity and outcome in patients with LRTI. Materials and methods, Five hundred and forty-five consecutive patients with LRTI and 50 healthy controls were evaluated. Serum copeptin levels were measured with a new chemiluminescens sandwich immunoassay. Results, Of the 545 patients, 373 had community-acquired pneumonia (CAP), 60 acute exacerbations of chronic obstructive pulmonary disease (COPD), 59 acute bronchitis, 13 exacerbations of asthma and 40 other final diagnoses. Copeptin levels were significantly higher in patients with LRTI as compared to controls (P < 0·001) with highest levels in patients with CAP. Copeptin levels increased with increasing severity of CAP, as classified by the pneumonia severity index (PSI) (P < 0·001). In patients who died, copeptin levels on admission were significantly higher as compared to levels in survivors [70·0 (28·8,149·0) vs. 24·3 (10·8,43·8) pmol L,1, P < 0·001]. The area under the receiver operating curve (AUC) for survival was 0·75 for copeptin, which was significantly higher as compared to C-reactive protein (AUC 0·61, P = 0·01), leukocyte count (AUC 0·59, P = 0·01) and similar to procalcitonin (AUC 0·68, P = 0·21). Conclusions, Copeptin levels are increased with increasing severity of LRTI namely in patients with CAP and unfavourable outcome. Copeptin levels, as a novel biomarker, might be a useful tool in the risk stratification of patients with LRTI. [source]

Climate and respiratory disease in Auckland, New Zealand

AUSTRALIAN AND NEW ZEALAND JOURNAL OF PUBLIC HEALTH, Issue 6 2009
Ashmita Gosai
Abstract Objective: Increases in the incidence of diseases are often observed during the cold winter months, particularly in cities in temperate climates. The study aim is to describe daily, monthly and seasonal trends in respiratory hospital admissions with climate in Auckland, New Zealand. Methods: Daily hospital admissions for total respiratory infections or inflammations (RII), total bronchitis and asthma (BA), and total whooping cough and acute bronchitis (TWCAB) for various age groups and ethnicities were obtained for the Auckland Region and compared with climate parameters on daily, monthly and seasonal time scales. Results: Seasonal and monthly relationships with minimum temperature were very strong (p<0.001) for RII over all age groups, for BA in the older age groups (14-64, 65+) and for TWCAB in the <1 year old age group. European, NZ M,ori and Pacific Islanders all showed increases in admissions as temperatures decreased. Pacific Islanders were particularly susceptible to RII. There was a lag in admissions of three to seven days after a temperature event. Conclusions and Implications: Results show that increases in respiratory admissions are strongly linked to minimum temperatures during winter, typical of cities with temperate climates and poorly-insulated houses. There are implications for hospital bed and staffing planning in Auckland hospitals. [source]

Efficacy and tolerability of EPs 7630 in patients (aged 6,18 years old) with acute bronchitis

ACTA PAEDIATRICA, Issue 4 2010
A randomized, double-blind, placebo-controlled clinical dose-finding study
Abstract Aim:, For EPs-7630, a herbal drug preparation from Pelargonium sidoides roots, therapeutic effects in respiratory tract infections outside the strict indication for antibiotics have already been demonstrated in adults. Now, a dose-finding study for EPs-7630 was performed in children and adolescents. Methods:, A total of 400 patients (aged 6,18 years) were randomized to receive either 30 mg, 60 mg or 90 mg EPs-7630 or placebo daily. Primary outcome criterion was the change in the Bronchitis Severity Score (BSS) from day 0 to day 7. Results:, After 7 days of treatment, the change in the BSS total score was significantly better in the 60 mg and 90 mg groups compared with placebo that of the without relevant differences between these two dosages. Especially ,coughing', ,sputum' and ,rales at auscultation' improved under EPs-7630. Onset of effect was faster, time of bed rest shorter and treatment outcome and satisfaction with treatment were rated better. Tolerability was comparable with placebo in all treatment groups. Conclusion:, EPs-7630 is effective in acute bronchitis outside the strict indication for antibiotics in 6,18 years old patients, with a dose of 60 mg or 90 mg daily offering the best benefit/risk ratio. EPs-7630 significantly reduces the severity of symptoms, leads to a more favourable course of the disease and a faster recovery from acute bronchitis compared with the placebo, and is well tolerated. [source]